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We evaluated the performance of the ELISA technique in the detection of IgA antibodies against different
Mycobacterium tuberculosis antigenic preparations in serum samples from 49 patients with pulmonary tuberculosis
collected before and after the start of specific treatment. The controls consisted of serum samples from healthy
patients without any prior contact with the bacteria and serum samples from patients with other pneumopathies.
Glycolipid antigen gave the best diagnostic performance, with a sensitivity of 88% and specificities varying from 88
to 100% in the control groups. These antigens constitute a powerful tool for the diagnosis and monitoring of
patients with pulmonary tuberculosis.
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There are many different mechanisms involved in
immunological defense against Mycobacterium tuberculosis.
The result of the interaction of these mechanisms and bacillus
virulence factors determines whether acute or asymptomatic
latent infection is established. Among the risk factors for
individuals in the latent phase to develop the disease are
infection by the human immunodeficiency virus (HIV),
malnutrition, diabetes mellitus and the use of
immunosuppressive drugs. Conditions such as immunological
deficiencies of a genetic nature or genetic conditions related
to the HLA system, for example, also lead to greater
susceptibility to development of active tuberculosis [1].
During airway contamination, the bacilli can adhere to and
invade the mucosa in the respiratory tract [2]. Depending on
the individual’s characteristics and the particular antigen
involved in the stimulation, cellular or humoral responses may
be activated. Although the role of secretory IgA in protecting
mucosal surfaces is widely accepted, the role of serum IgA
has been little investigated. This immunoglobulin may be
involved in removing antigens from the circulatory system
and transferring them to the bile [3]. In addition, it has been
shown that this antibody has the ability to opsonize and
agglutinate the antigen and to fix complement [4]. IgA response
is particularly interesting, as this immunoglobulin has been
shown to be produced in large quantities in patients with
active pulmonary disease.
Control of tuberculosis depends mainly on the rapid
detection and treatment of active cases. Given that 90% of the
clinical forms are pulmonary and that transmission takes place
via the airways, early diagnosis is an important means of
controlling the disease.
Currently, diagnosis is based on clinical findings and
laboratory tests. Traditional microbiological diagnostic
methods have a number of limitations when used to detect
microorganisms, particularly in patients with paucibacillary
tuberculosis or extrapulmonary forms of the disease.
Furthermore, because of the high prevalence of non-
tuberculous mycobacteria, the long time required for bacterial
growth and species identification using biochemical tests in
material from coinfected patients makes these tests difficult
to perform [5-7].
The purified protein derivative (PPD) used in intradermal
tuberculin tests to detect delayed-type hypersensitivity (the
Mantoux test) has limited diagnostic value, as clinically healthy
individuals can have a positive tuberculin test (PPD) (> 10mm),
without this reactivity being reflected in tests for specific
antibodies [8-10]. Furthermore, people who have been
vaccinated with bacillus Calmette-Guérin (BCG) and/or have
been in contact with other species of mycobacteria can have
positive results as well [11].
Molecular methods for detecting the structural
components of the bacteria have limitations related to cost
and reproducibility, which makes their use on a large scale
difficult. Serological tests based on the detection of antibodies
are promising because they do not depend on the detection
of mycobacteria, are both quick and sensitive, are easy to
perform and are cheaper than tests based on the amplification
of nucleic acids. In addition, they allow diagnosis of
paucibacillary and extrapulmonary tuberculosis and can be
used to detect the active phase of the disease. In this context,
the choice of antigen is important, and all the characteristics
of the response kinetics must be assessed to ensure the best
interpretation of the results.
Given the limitations of traditional methods and the need
for a better understanding of the response of IgA in human
pulmonary tuberculosis, the objective of this study was to
investigate whether this class of immunoglobulin could be
used as a marker for the acute form of the disease and to
identify variations in the level of such immunoglobulins during
the clinical evolution of patients receiving therapy. The
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following three mycobacterial antigens were used in our
study: glycolipid, recombinant protein, and crude antigen
obtained, by sonication, from a culture of M. tuberculosis.
Material and Methods
Study Population
The sera samples used in this study were collected from
June 2000 to April 2002. The study was approved by the local
ethical committee of the Hospital das Clinicas de São Paulo.
Written informed consent was obtained from each participant.
Group I – Patients with Tuberculosis
Fifty-two patients with clinical symptoms suggestive of
tuberculosis, with an average age of 36 years (minimum 14
and maximum 75 years), who had been seen in the outpatient
unit at the Hospital das Clínicas, São Paulo, SP, and had had
their diagnosis confirmed by direct sputum-smear microscopy
and/or culture and the species identified by microbiological
or molecular analysis were included. When direct sputum
examination was not possible, cytology of bronchial alveolar
lavage, lung biopsy or lymph node puncture was performed.
All the patients had negative HIV serology.
Forty-eight serum samples were collected from patients
with pulmonary tuberculosis (n=44) and tuberculous
lymphadenitis (n=4) before the treatment started. Serological
follow-up was carried out by collecting blood samples at two
distinct times, namely, after two months of treatment and at
the end of the treatment (after six months), as advocated by
WHO. Serum samples were collected from 42 patients with
pulmonary tuberculosis and from four with tuberculous
lymphadenitis.
Group II – Control Group
We analyzed serum samples from 20 individuals considered
healthy who declared that they had not had any contact with
patients with pulmonary tuberculosis, whether relatives or
not, and did not have any clinical symptoms of tuberculosis
at the time they were included in our study. Tuberculin tests
(PPD) were not carried out in these individuals.
Group III – Patients with Other Pneumopathies (N = 49)
Serum samples from patients with other pulmonary
diseases for whom the possibility of pulmonary tuberculosis
had been excluded were collected in the pneumology
outpatient unit at the Hospital das Clínicas, São Paulo.
Group IV – Contacts (N=25)
Nine serum samples were collected from individuals who
had been exposed to tubercular patients during the course of
their work and 16 samples from individuals who had come
into contact with patients with active tuberculosis. Although
tuberculin tests (PPD) were requested, these could not be
carried out in all the individuals in this group. Patients had
difficulty adhering to the study because they had to return to
the outpatient unit for the skin tests to be carried out and
subsequently read (72 hours). Consequently, this parameter
was not taken into account in the analysis.
M. tuberculosis antigens
Whole-protein antigens were obtained after culturing a
clinical strain of M. tuberculosis isolated in 2000 and
characterized by microbiological and molecular methods, as
described by Beck in 2005. The recombinant antigen
combination TbF6/DPEP was supplied by Corixa Corp., Seattle,
WA, USA.
Glycolipid antigen, purified according to WATANABE et
al, 1995, on Nunc PolySorp plastic plates, was supplied by the
R&D department at bioMérieux SA exclusively for use in this
study.
ELISA (Enzyme -Linked Immunosorbent Assay)
Flat-bottomed polystyrene plates (Nunc – Immuno Module
Maxisorp F 16, DENMARK) were sensitized with the whole-
protein antigen or recombinant antigen using 100µL/well at
the appropriate concentrations for each antigen (whole-protein
antigen at a concentration of 0.5µg/well and recombinant
antigen at a concentration of 400ng/well), diluted in a 0.06M
pH 9.6 carbonate/bicarbonate buffer and incubated for two
hours at 37°C and again for 18 hours at 4°C. The antigen
solution was removed and the wells blocked for two hours at
37°C with buffer phosphate saline (PBS) containing 5% skim
milk. The plates were then washed with PBS-T (PBS containing
0.05% Tween 20), followed by two washes with distilled water.
The plates were placed in an incubator at 37°C for 4 hours,
wrapped individually in aluminum foil, sealed and kept at 4°C
until use.
To carry out the test with the whole-protein antigen and
recombinant antigen, the sensitized plates were incubated with
100µL of the sera diluted 1/20 in PBS containing 2% skim milk.
After incubation for 30 minutes at 37 °C in a moist chamber,
the sera were removed and the plates washed five times with
PBS-T. The anti-IgA enzymatic conjugate diluted 1/7,500 in
the same diluent as the serum was then added (100µL/cavity).
After incubation at 37°C for 30 minutes in a moist chamber
and a new cycle of washes, 100µL/well of the chromogenic
substrate tetramethylbenzidine/hydrogen peroxide (TMB/
H2O2) was added and the plate was incubated for an additional
30 minutes at 37°C in a moist chamber kept in the dark. The
enzymatic reaction was stopped by adding 50µL of 2N
sulphuric acid, and the plates read at 450nm in a Titertek
microplate reader.
To carry out the test with glycolipid antigen, the plates
were incubated with 100µL of the sera diluted 1/250 in PBS
containing 2% BSA. After incubation for 30 minutes at 37°C
in a moist chamber, the sera were removed by quickly turning
the plates upside down and washing them six times with PBS-
T and three times with bidistilled water. The anti-IgA enzyme
conjugate, diluted 1/7,500 in the supplied diluent, was then
added (100µL/well). After incubation at 37°C for one hour in a
moist chamber, followed by a new cycle of washes, 100µL/
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well of the chromogenic solution O-phenylenediamine
dihydrochloride with hydrogen peroxide (OPD/H2O2) was
added and the plate was incubated for 30 minutes at ambient
temperature in the dark. The enzymatic reaction was stopped
by adding 50µL of 2N sulphuric acid, and the plates were read
at 492nm in a Titertek microplate reader.
The threshold for the test was obtained using the samples
from patients with tuberculosis in pretreatment (n = 48) and
from healthy patients (n = 20). The cutoff was set at two
standard deviations above the mean of the optical densities
(O.D.) for sera from healthy individuals based on analysis of
the ROC (Receiver Operating Characteristic) curve using
Win Episcope 2.0 software.
Statistical Analysis
The results were expressed as percentages when
appropriate. The optical densities were calculated and a p
value < 0.05 was considered statistically significant for all
tests.
Results
To define the reactivity threshold more accurately, ROC
curves were drawn, taking into account the cutoff points
established with one and two standard deviations and the
interval between them, to find a value that would improve the
test’s specificity without a significant loss of sensitivity. It
can be seen in Figure 1 that the glycolipid antigen had the
largest area under the curve (99.4%), with a sensitivity of 88%
and a specificity of 100%.
After the reactivity threshold had been determined for the
different antigens, using sera from healthy individuals, the
ELISA test was carried out on sera from patients with other
pneumopathies and from contacts.
A 2 x 2 contingency table was used to calculate Youden’s
J index, which evaluates the diagnostic efficiency of the tests
used. The glycolipid antigen had the highest J index, followed
by TBF6/DPEP and the whole-protein antigens.
The glycolipid and recombinant (TBF6/DPEP) antigens had
the best specificity values when the serum samples from healthy
individuals were studied (100 and 90%, respectively). There
was a noticeable drop in the specificity of the recombinant
proteins, however, in the group that included other
pneumopathies (74%) and in the contacts (88%, Table 1).
The glycolipid antigen (PGL-Tb1) had the smallest
variation in specificity among the groups analyzed; the
specificity for healthy individuals was 100%, 88% for patients
with other pneumopathies, and 80% for individuals who had
had contact with patients with active tuberculosis,
corresponding to an overall specificity of 89%.
Serological follow-up to determine IgA reactivity to M.
tuberculosis was conducted in 50/52 patients. The median
optical densities (MdOD) for the total protein antigen were
similar at each of the three serological follow-ups (Figure 2,
p>0.05, Kruskal-Wallis method); the MdOD for the TBF6/DPEP
and glycolipid (PGL-Tb1) antigens were different at each of
the three follow-ups. The MdOD for ELISA with glycolipid
antigen were found to differ significantly between the first,
second and third serum samples (p< 0.0062, Dunn’s method).
Figure 3 shows the median absorbances during serological
follow-up of the patients using glycolipid antigen. The drop
in reactivity between the first samples (pretreatment), the
samples at two months and the samples at the end of the
treatment (six months on average) was significant (p =
0.00000466, Friedman repeated-measures method).
Of the 44 patients with active pulmonary tuberculosis, 35
were sputum-smear positive, eight were negative, and for one
patient the result of the sputum smear test was not available.
The glycolipid antigen had the best performance; it detected
91% of the cases of pulmonary tuberculosis (40/44), made up
of 33 of the 35 patients with positive sputum smears and seven
of the eight with negative sputum smears.
Figure 4 shows the median optical densities for serum
samples from patients with pulmonary tuberculosis and
positive sputum smears and patients with negative sputum
smears. Significant differences were found when whole-
protein and glycolipid antigen was used (p=0.012 and p=0.034,
respectively, non-parametric Mann-Whitney test).
Discussion
Studies have shown that IgG1 and IgA antibodies are
formed in response to various mycobacterial products,
including components of the cell wall. This underlines the
need to examine the role of humoral immunity in mycobacterial
infections in greater detail [9,14,15].
We evaluated the performance of ELISA tests using the
following three antigens: recombinant antigen combination
(TBF6/DPEP), glycolipid antigen and whole-protein antigen
produced from soluble proteins obtained after sonication of a
clinical strain of M. tuberculosis. After protocols had been
defined, we used standardized tests with serum samples from
healthy individuals (n=20) to determine the cutoff for the tests.
As in other studies [10], the ROC curve was used to determine
the best specificity values for the tests without a major loss in
sensitivity and to identify the most accurate test (Figure 1).
Julian et al. (2002) showed that adult tuberculosis patients
have a specific IgA response to glycolipid antigens. However,
they found that tests detecting immunoglobulin A had lower
sensitivity (66%) and greater specificity (88%) than IgG. The
sensitivity and specificity found in our study were 88 and
89%, respectively.
While not considered ideal for use in commercial tests,
the sensitivity of the IgA ELISA was within the range
recommended by WHO (greater than 80% when the reference
is IgG antibody detection). However, the six sera from
tuberculosis patients that were not considered to be reactive
by the IgA ELISA with glycolipid antigen had optical density
values close to the reactivity threshold (20%).
A number of factors can influence the reactivity of the
test, such as the patient’s immunological “status” and the
stage and duration of the disease at the moment that the
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Figure 1. Evaluation of three antigens using ELISA by
Receiver Operating Characteristic (ROC) Curves.
Figure 2. Median optical densities (MdOD) observed in the
analysis of sera from 50 patients at the different serological
follow-ups for different antigens. MdOD 1st sample = MdOD
of the samples collected before therapy had started; MdOD
2nd sample = MdOD of the samples collected during the 2nd
month of treatment; MdOD 3rd sample = MdOD of the samples
collected at the end of treatment.
Figure 3. Median OD values for IgA ELISA using glycolipid
antigen during serological follow-up of patients with active
tuberculosis. T0 = samples collected before treatment; T2 =
samples collected during the 2nd month of treatment; T6 =
samples collected at the end of treatment.
patient was included in the study [16-18]. When the ELISA
tests using different antigens were carried out with sera from
groups III and IV, there was less variation in specificity with
the glycolipid antigen (88%-100%). In studies where there is a
significant number of samples from groups III and IV,
variations in specificity as a result of deregulation of the
immune system are often found [18-20].
Studies carried out by BECK (2005) to detect IgG antibodies
against a recombinant antigen combination (TBF6/DPEP)
revealed sensitivity and general specificity values of 85% and
91%, respectively. In our study, we also found that the IgA
response against this antigen combination had a noticeably
higher specificity for the healthy individuals than for the
contacts and individuals with other pneumopathies; it varied
from 74% to 90%. The false-positive reactions in the group of
individuals with other pneumopathies can also be attributed
to the presence of hypergammaglobulinemia, which is common
in nontuberculous pneumonias [21].
 IgA Response to M. tuberculosis Antigens
Table 1. ELISA parameters for IgA antibodies anti-Mycobacterium tuberculosis using three different antigens.
Antigens Cut-off S (%) Population Sp (%) PPV (%) NPV (%) J index
Whole-protein: 0.370 69 Healthy 75 88 48
Contacts 72 78 55 0.40
OP 55 62 63
TBF6/DPEP 0.450 58 Healthy 90 94 45
Contacts 88 91 66 0.48
OP 74 71 63
Glycolipid 0.137 88 Healthy 100 100 77
Contacts 80 92 75 0.88
OP 88 87 87
S = sensitivity; Sp= specificity; PPV = positive predictive value, NPV = negative predictive value; OP = other pneumopathies;
J index = calculated with the general specificity value.
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The whole-protein antigen had a lower specificity value,
and there was greater variation in this parameter among the
control groups. This can be explained by the many antibodies
that can be produced for the different species of mycobacteria
that share epitopes with M. tuberculosis. Although the
population in Brazil is vaccinated with an attenuated strain of
bacillus Calmette-Guérin (BCG), the antibodies produced by
immunization do not appear to interfere in the reactivity when
sera from vaccinated individuals are tested by ELISA [10,22-
24] and are not involved in the positive reactions found in the
control group in our study.
Youden’s index showed that the glycolipid antigen had
the best diagnostic efficiency. However, as the mycobacterial
antigens that were analyzed have different molecular
structures, there was no correlation between the serological
results for the different tests.
Various studies report the presence of IgA antibodies
against M. tuberculosis as a marker of recent infection, while
others refer to extensive, active infection and miliary
tuberculosis [9,17,25]. The former hypothesis appears to be
related to the fact that this immunoglobulin is secreted during
initial contact with the bacillus on mucosal surfaces (secretory
IgA) and that mycobacterial antigens (such as glycolipids)
interact with specific receptors in the host-defense cells,
stimulating the release of cytokines (IL-4, 6 and 10) that have
adjuvant effects, such as inducing immunoglobulin isotype
switching (IgM to IgA) [26]. However, inour study IgA
antibodies against the glycolipid antigen were detected
irrespective of the time of onset of the symptoms (0 to 24
months), suggesting that the IgA response is present in both
recently acquired infections and those reported more than
two years previously and is thus more associated with active
disease.
Although the stage and duration of infection are important
factors in determining the presence of the immunoglobulin,
other factors, such as the formation of immune complexes, the
characteristics of the individual’s immune system and genetic
factors, particularly those related to the HLA system, can also
interfere with the humoral response against glycolipid antigen.
Although the number of cases of pulmonary tuberculosis
patients with a negative smear test was small in our study, we
found that the glycolipid antigen had the best performance in
the IgA ELISA. Alifano et al. (1997) studied IgA response
against Kp-90 antigen in patients with negative smear tests
and reported a sensitivity of approximately 68%. As also
found in other studies, most of the patients with negative
sputum smears who were positive in the IgA ELISA in our
study had pulmonary infiltrates without cavity lesions.
Figure 4. Median ODs observed in the ELISAcompared with the results of sputum-smear microscopy. A p value < 0.05 was
considered significant (Mann – Whitney test).
 IgA Response to M. tuberculosis Antigens
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The heterogeneity of the immune response can be explained
by the different types of antigen released by the mycobacteria
during the various stages of the disease. Cavity lesions have
different stages of liquefaction and can vary in terms of the
amount of bacilli in the cavity, bacillary replication and the
metabolic changes that can take place [27].
After two and six months of therapy, a drop in serological
reactivity for the ELISA IgA with glycolipid antigen (Figure 3)
was observed in the serum samples from patients with
tuberculosis. Most of the drugs used to treat tuberculosis act
on the components of the cell wall. Glycolipids are present on
the outermost surface of the mycobacteria and are therefore
an easy target for therapeutic agents. Arikan et al. (1998)
showed that anti-Kp90 IgA antibodies have a promising role
in monitoring tuberculosis therapy.
The IgA ELISA had different results for the three antigens
evaluated. The many different protein fractions present in the
whole-protein antigen extract may explain its greater reactivity.
We found that three patients were reactive for the crude and
glycolipid antigen, making it important to analyze these
patients more accurately, as despite the absence of clinical
symptoms they might be developing latent tuberculosis.
Although IgA ELISA with glycolipid antigen gave the best
results, we believe that the specificity of the test can be
improved by using more specific glycolipid antigens that are
only present in M. tuberculosis extract, by avoiding
contamination during the antigen purification process and by
preabsorption of the serum with mycobacteria other than M.
tuberculosis. Our results suggest that IgA antibodies have
potential clinical value for monitoring tuberculosis therapy,
as 40% of the patients with tuberculosis in the study had a
drop in reactivity during the follow-up period and 20% had
negative serology at the end of the treatment.
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